Avet Pharmaceuticals Recalls Tetracycline HCl Capsules USP, 250 mg and 500 mg

News
Article

The company is recalling Tetracycline HCl Capsules USP, 250 mg and 500 mg, 100-count bottles because of failed dissolution specifications.

Avet Pharmaceuticals (East Brunswick, New Jersey) is voluntarily recalling Tetracycline HCl Capsules USP, 250 mg and 500 mg, 100-count bottles because of low out-of-specification dissolution test results. The recalled product was distributed under the Heritage Pharmaceuticals label nationwide in the United States between August 2019 and March 2020.

Tetracycline HCl Capsules USP, 250 mg and 500 mg are used to treat infections, including upper and lower respiratory infections, and according to the company, low dissolution may result in less drug in the patient, which could cause treatment failure. “For patients with compromised immune systems and the elderly, who may be taking tetracycline to treat a serious infection such as pneumonia, there is a reasonable probability that if there is not enough tetracycline in the body to fight the infection, this could result in rapid progression of the infection and death,” the company said in a press release.

The company has not received adverse event reports or complaints related to the recalled product. Adverse events may be reported to FDA through its MedWatch program.

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes